Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Karen L SmithFengmin ZhaoIngrid A MayerAmye J TevaarwerkSofia F GarciaCarlos L ArteagaWilliam F SymmansBen H ParkBrian L BurnetteDella F MakowerMargaret BlockKimberly A MorleyChirag R JaniCraig MescherShabana J DewaniUrsa Brown-GlabermanLisa E FlaumErica L MayerWilliam M SikovEve T RodlerAngela M DeMicheleJoseph A SparanoAntonio C WolffKathy D MillerLynne I WagnerPublished in: Cancer (2024)
Despite the similar frequency of clinician-rated AEs, PROs identified greater on-treatment symptom burden with capecitabine and complemented clinician-rated AEs by characterizing patients' experiences during chemotherapy.
Keyphrases
- patient reported outcomes
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- phase ii study
- peritoneal dialysis
- phase iii
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- rectal cancer
- clinical trial
- metastatic breast cancer
- risk factors
- radiation therapy
- open label
- replacement therapy